ストックスクリーナーアプリを入手
11.25
3.93%
-0.46
前日終値:
$11.71
開ける：
$11.75
24時間の取引高:
1.30M
Relative Volume:
0.92
時価総額：
$1.46B
収益：
当期純損益:
株価収益率:
-18.48
EPS:
-0.6087
ネットキャッシュフロー:
1週間 パフォーマンス:
-3.10%
1か月 パフォーマンス:
-11.42%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.16
$11.79
1週間の範囲:
$10.44
$11.79
52週間の値動き範囲:
$9.76
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Compare KLRA vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.25 | 1.46B | 0 | 0 | 0 | -0.6087 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-12 | 開始されました | Evercore ISI | Outperform |
| 2026-05-12 | 開始されました | JP Morgan | Overweight |
| 2026-05-12 | 開始されました | Jefferies | Buy |
| 2026-05-12 | 開始されました | Leerink Partners | Outperform |
| 2026-05-12 | 開始されました | TD Cowen | Buy |
| 2026-05-12 | 開始されました | William Blair | Outperform |
すべてを表示
Kailera Therapeutics Inc (KLRA) 最新ニュース
Kailera Therapeutics (Nasdaq:KLRA)Stock Analysis - Simply Wall Street
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - stocktitan.net
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - TechStock²
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Archives - 24/7 Wall St.
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - Yahoo Finance
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
2 GLP-1 Stocks That Could Double Your Money by 2031 - The Motley Fool
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - stocktitan.net
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Australia
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Canada
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com India
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com UK
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings | KLRA Stock News - Quiver Quantitative
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - GlobeNewswire
Kailera Therapeutics Inc (KLRA) 財務データ
Kailera Therapeutics Inc (KLRA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Kailera Therapeutics Inc (KLRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
3.77%
4.63%
大文字化:
|
ボリューム (24 時間):